Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
BRCA1/2&DNA Repair Gene Testing
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
FDA approved trastuzumab deruxtecan for HER2-positive breast cancer 2020-01-22
Trastuzumab deruxtecan received FDA approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.
Veliparib plus carboplatin and paclitaxel showed clinically meaningful benefit in HER2 negative breast cancer patients with BRCA mutation 2020-01-22
A combination of veliparib, carboplatin, and paclitaxel significantly improve the PFS of breast cancer patients who had low HER2 expression and a BRCA mutation in phase 3 BROCADE3 study.
Tucatinib triplet reduces risk of death in metastatic HER2-positive breast cancer 2020-01-22
HER2-positive breast cancer patients have limited treatment options after therapy with multiple HER2-targeted agents. In the HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine showed clinicl benefit in heavily pretreated HER2-posit
A new targeted therapy for advanced gastrointestinal stromal tumors (GIST) 2019-12-30
Ripretinib is a novel tyrosine kinase inhibitor that was designed to target KIT and PDGFRα-mutated kinase. A phase III study (INVICTUS) showed that ripretinib improved PFS and OS compared with placebo in patients with GIST progressed with more than three
Maintenance olaparib with bevacizumab improves progression-free Survival in patients with newly diagnosed ovarian cancer 2019-12-30
In phase 3 PAOLA-1 trial, olaparib plus bevacizumab as first-line maintenance therapy significantly prolongs the progression-free survival of ovarian cancer patients.
Neratinib ± fulvestrant was effective in patients with advanced breast cancer and HER2 mutations 2019-12-30
The plasmaMATCH trial is a phase 2a, open-label, multicentre trial in patients with advanced breast cancer. The trial aims to evaluate whether certain genetic mutation identified through ctDNA could benefit patients from matched targeted treatments. In th
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
